ARB 1002
Alternative Names: ARB-1002Latest Information Update: 31 Jan 2025
Price :
$50 *
At a glance
- Originator Arbele
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 18 Dec 2024 Preclinical trials in Cancer in Hong Kong (Parenteral) before December 2024 (Arbele pipeline, December 2024)
- 18 Dec 2024 US FDA approves IND application for ARB 1002 in Cancer (Arbele pipeline, December 2024)